How Valkyrie BioScience is bringing advanced chairside imaging, intelligent software, and a more connected approach to dental diagnostics into focus
For decades, dental professionals have relied on X-ray imaging to understand what is happening beneath the surface. Yet even a familiar, essential tool has its limitations. A conventional two-dimensional image can leave anatomical details obscured by overlapping structures, making some clinical situations more difficult to evaluate.
Valkyrie BioScience is working to address that challenge by rethinking how dental professionals capture and use diagnostic information. Through its LUMOS 3DX chairside Tomosynthesis platform and its broader Intelligent Imaging™ strategy, the company is developing an approach that brings additional anatomical visualization closer to the point of care while laying the groundwork for more connected, software-driven diagnostics.
For Michael Stevens, CEO and Chairman of Valkyrie BioScience, the opportunity extends beyond introducing another imaging device. It is about helping clinicians move from simply capturing images to making better-informed decisions about patient care.
“We started with the ambition to change how dentists see,” Michael Stevens explains in his leadership responses. “Today, our vision is to change how dentistry diagnoses, connects information, and delivers patient care.”
That shift in perspective captures the direction of a company that began with a focused imaging concept and is now pursuing a broader role in dental technology.
From an Imaging Innovation to a Broader Vision
Valkyrie BioScience began in 2019 as 3Dio, founded by Clark Turner, an innovator in dental imaging known for his work on the NOMAD handheld dental X-ray system. The company’s early vision centered on exploring new ways to help dental professionals visualize anatomical structures and access diagnostic information beyond what conventional imaging could provide.
One of the innovations to emerge from that work was LUMOS 3DX, a chairside Tomosynthesis platform designed to produce sectional images from multiple X-ray projections captured at different angles.
As the company developed, its ambitions expanded. Rather than concentrating on a single imaging product, Valkyrie BioScience began building a broader portfolio that includes Tomosynthesis, conventional cone beam computed tomography (CBCT), and technologies in development. Artificial intelligence, cloud-based software, and connected diagnostic tools also became central to its longer-term direction.
The transition from research and development toward commercialization marked an important step. According to the company’s responses, LUMOS 3DX reached the market in September 2026, alongside efforts to expand the imaging portfolio, strengthen clinical relationships, and build commercial capabilities.
“What excites me most is that our original mission has never changed. We’ve simply expanded what we believe is possible,” Michael states.
The distinction matters. The company’s strategy is not simply to develop a new product category, but to explore how imaging hardware, software, and clinical information might work together to support the everyday decisions dental professionals make.
Looking Beyond the Limits of Two-Dimensional Imaging
Traditional dental X-rays remain an important diagnostic tool. However, their two-dimensional format can compress complex anatomical structures into a flat image. Teeth, bone, and surrounding anatomy may overlap, making some details harder to distinguish.
Advanced imaging can provide additional perspectives, but conventional CBCT systems may involve higher costs, dedicated space, and changes to a practice’s existing workflow. The company sees an opportunity between these established options: provide additional anatomical visualization in a format designed to fit more naturally into everyday dental care.
Its LUMOS 3DX platform uses Tomosynthesis to capture multiple X-ray projections and reconstruct them into sectional images. The aim is to help clinicians examine structures that may be difficult to evaluate on conventional two-dimensional radiographs because of overlapping anatomy.
The company positions the technology as a complementary diagnostic option, not a universal replacement for either traditional radiography or full CBCT. Each modality has its own clinical role, and the appropriate choice depends on the individual case and the information a clinician needs.
This approach reflects a practical consideration in dental technology. Innovation must offer a useful clinical purpose, not simply introduce more sophisticated equipment.
“At Valkyrie BioScience, we don’t believe the future of dental imaging is simply about taking a better X-ray,” Michael Stevens explains. “It’s about helping dentists see more, understand more, and make better-informed decisions that benefit their patients.”
Bringing Advanced Imaging Closer to the Patient
One of the defining features of LUMOS 3DX is its chairside design. Rather than treating advanced imaging as a separate step in the patient journey, the platform is intended to bring additional visualization closer to the point of care.
That can be meaningful in a busy dental practice, where time, space, and workflow all influence how new technology is adopted. A system must do more than produce useful images. It also needs to be practical for dental teams to operate and fit into the rhythm of appointments.
Valkyrie BioScience emphasizes intuitive design, mobility, hands-on training, and ongoing customer support as part of this effort. Its broader objective is to help clinicians access additional diagnostic information without introducing unnecessary complexity into their daily routines.
The potential value also extends to conversations between dentists and patients. Dental findings are not always easy for patients to understand, particularly when they appear on conventional X-rays. Additional sectional views may help clinicians explain anatomical structures, discuss their observations, and communicate treatment considerations more clearly.
Better visualization does not eliminate the need for clinical expertise. Instead, it can give dentists another way to explain what they see and why a particular course of action may be appropriate.
For Valkyrie BioScience, technology is most useful when it supports both the clinical process and the relationship between the clinician and the patient.
Intelligent Imaging: Connecting Hardware, Software, and Clinical Insight
LUMOS 3DX is part of a larger strategy the company calls Intelligent Imaging™. The idea is to look beyond image acquisition and explore how diagnostic information can be organized, evaluated, shared, and incorporated into clinical decision-making.
Artificial intelligence is expected to play an important role in that development. Valkyrie BioScience is working toward AI-assisted tools that could help clinicians identify potential areas of concern, evaluate imaging findings, and interpret diagnostic information more efficiently. These capabilities are intended to support professional judgment rather than replace it.
That distinction is particularly important in healthcare, where emerging technologies must be developed responsibly and their intended uses clearly understood. The company identifies clinical validation, regulatory compliance, data security, and transparency as priorities as it advances its software capabilities.
Cloud-based technology is another part of the strategy. The company envisions connected tools that can help dental practices manage imaging information, support collaboration, and improve access across multiple locations. Such capabilities could be particularly relevant to dental service organizations and practices operating across several sites.
The company also sees opportunities to make its platform more valuable over time through software updates, additional functionality, and software-as-a-service offerings. Rather than viewing an imaging system as a standalone equipment purchase, the longer-term ambition is to develop an evolving diagnostic platform.
These plans remain part of a broader technology roadmap. Their success will depend on development, validation, practical implementation, and the ability to deliver meaningful value in clinical settings.
Building Technology Around Real Clinical Needs
For a medical technology company, a promising idea is only the beginning. Products must address genuine clinical needs, meet applicable regulatory requirements, and earn the confidence of the professionals expected to use them.
Valkyrie BioScience says its product development process draws on input from practicing dentists, specialists, clinical advisors, and industry experts. Their feedback can inform product design, imaging capabilities, software functionality, and workflow improvements.
The company also emphasizes engineering verification, risk management, appropriate clinical and performance validation, and quality throughout the product lifecycle. These considerations extend from research and development through manufacturing, testing, installation, training, and customer support.
The approach recognizes that a product launch is not the end of development. Real-world use can reveal opportunities to improve usability, address practical challenges, and refine the experience for clinicians and their teams.
“Trust is earned through innovation, clinical validation, regulatory discipline, and an unwavering commitment to quality,” Michael Stevens states.
That philosophy also shapes the company’s plans for clinical education. Through demonstrations, seminars, clinical case presentations, professional publications, and industry events, the company aims to help dental professionals understand where its technologies may fit into practice.
Its commercial strategy is intended to complement this educational effort. The company is expanding sales capabilities and building relationships with clinicians, dental organizations, and other industry partners. The goal is to develop long-term customer relationships grounded in clinical relevance and practical value, rather than focusing solely on equipment sales.
Valkyrie BioScience also lists the Dental Product Report 2026 Product of the Year recognition among its company highlights.
Turning Innovation Into Sustainable Growth
Over the next three to five years, Valkyrie BioScience plans to pursue growth across several connected priorities: commercial expansion, product development, intelligent diagnostics, strategic partnerships, and entry into additional markets.
The company aims to strengthen adoption of LUMOS 3DX and its broader imaging portfolio, while continuing to develop complementary technologies. Its stated research and development ambition is to introduce one to two new products annually over the next five years, subject to its development roadmap.
Artificial intelligence and cloud-based software are expected to remain central to that work. The company also sees opportunities in recurring software revenue, additional clinical technologies, and partnerships that can help bring its products to a wider professional audience.
North America is the initial commercial focus, with international expansion forming part of the longer-term plan. Reaching new markets will require the right regulatory pathways, distribution relationships, manufacturing capabilities, and customer support infrastructure.
For Stevens and the wider leadership team, commercial execution is as important as the underlying technology. Developing an innovative product does not automatically guarantee adoption. Dental professionals need to understand its applications, trust its performance, and see how it fits their clinical and business needs.
The company’s evolution from a research-focused organization toward broader commercialization reflects that reality. Sustainable growth will depend on aligning product innovation with customer education, operational discipline, and consistent support.
A Future Measured by More Than Products
Valkyrie BioScience’s long-term ambition is to become more than a dental imaging manufacturer. It wants to connect advanced imaging, intelligent software, cloud-based capabilities, and clinical information into a more integrated diagnostic ecosystem.
At the center of that ambition is a straightforward idea: diagnostic technology should help clinicians understand more, communicate more effectively, and make informed decisions for their patients.
The company is particularly interested in the potential for earlier identification of concerns, more efficient treatment planning, and wider access to advanced visualization across general dentistry, specialty practices, and multi-location organizations. These are goals the company intends to pursue as its technology portfolio and clinical evidence develop.
The broader challenge is ensuring that innovation remains grounded in clinical needs. AI and cloud connectivity may open new possibilities, but their value will ultimately depend on reliability, responsible implementation, and the confidence they earn from the professionals using them.
For Valkyrie BioScience, the next phase is about turning years of development into practical tools that can demonstrate their value in everyday dentistry.
As Michael Stevens puts it, “Our mission is not simply to advance dental technology. It is to help advance the standard of dental care for generations to come.”
That ambition sets a high bar. The opportunity now lies in translating it into technologies that clinicians can trust, workflows they can use, and diagnostic insights that support better-informed patient care.
About Valkyrie BioScience
Founded in 2019 as 3Dio, Valkyrie BioScience is a dental technology company focused on advanced imaging and intelligent diagnostics. Its portfolio includes the LUMOS 3DX chairside Tomosynthesis platform and CBCT imaging technologies, while its longer-term strategy includes AI-assisted tools, cloud-based software, and connected diagnostic solutions. Headquartered in Lindon, Utah, the company aims to make advanced diagnostic visualization more practical and clinically useful for dental professionals.
Company Details
- Company Name: Valkyrie BioScience
- Founding Year: 2019
- Office Locations: 1443 West 40 South #200 Lindon UT 84042
- Official Website: www.valkyriebiosci.com
- Industry/ Sector: Dental/ Veterinary
Featured Leader’s Profile
- Name of the Featured Leader: Michael Stevens
- Designation: Chairman and Chief Executive Officer (CEO)
- Brief Background & Experience:
Over 30 years of leadership experience in the dental and healthcare industries, with a proven track record of building, scaling, and successfully exiting companies across capital equipment, artificial intelligence (AI), software, SaaS, and consumables.
Company Highlights
- Major Achievements or Recognitions: 2026 Product of year – Dental Product Report